A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis

NCT01214733 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche